Fluidigm Corporation provided preliminary unaudited revenue guidance for the fourth quarter and full year of 2014 and full year of 2015. The company announced total revenue for the fourth quarter of 2014 is expected to be approximately $33.4 million. Organic revenue for the fourth quarter of 2014 (excluding revenue attributable to the DVS Sciences acquisition, comprised of the CyTOF® 2 system and proteomics analytical consumables) is expected to be approximately $25.2 million.

Total revenue for the full year of 2014 is expected to be approximately $116.4 million. Organic revenue for the full year of 2014 (excluding revenue attributable to the DVS Sciences acquisition, comprised of the CyTOF® 2 system and proteomics analytical consumables) is expected to be approximately $95.9 million.

Fluidigm projects total revenue for the full year of 2015 to be between $142 million and $149 million. 2015 revenue projections incorporate an estimated negative currency related impact of 3% to 4% at the midpoint of the range.